Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akshay Binayke has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Awasthi

    Immunology Core Laboratory Translational Health Science and Technology Institute Faridabad India

    8 shared publications
  • Deepak Kumar Rathore

    Centre For Immunobiology and Immunotherapy Translational Health Science and Technology Institute NCR‐Biotech Science Cluster Faridabad India

    3 shared publications
  • Jyotsna Dandotiya

    Immunology Core Laboratory Translational Health Science and Technology Institute Faridabad India

    3 shared publications
  • Yashwant Kumar

    Translational Health Science and Technology Institute Faridabad India

    3 shared publications
  • Aymaan Zaheer

    Immunology Core Laboratory, Translational Health Science and Technology Institute, Faridabad, India

    2 shared publications
  • Charu Suri

    Centre For Drug Discovery (CDD) Translational Health Science and Technology Institute NCR‐Biotech Science Cluster Faridabad India

    2 shared publications

Latest Publications

  • Cholic Acid Reprograms RORγt + Th17 Cells into IL‐10‐Producing T Cells to Limit Experimental Colitis

    by Rajdeep Dalal, Srikanth Sadhu, Poonam Singla, Upasna Madan, Akshay Binayke, Charu Suri, Sucheta Goswami, Sandeep Goswami, Manas Ranjan Tripathy, Aarzoo Kamboj, et al.

    Inflammatory bowel disease (IBD) is a relapsing‐remitting inflammatory disorder of the gastrointestinal tract driven by dysregulated T helper (Th)‐cell responses, gut microbiota imbalance, and altered bile acid metabolism. While cholic acid (CA), a primary bile acid, is immunotoxic at high concentrations, its immunomodulatory role at physiological levels remains unclear. Here, we evaluate the therapeutic potential of CA in an experimental colitis model. Administration of biologically tolerable CA significantly reduced disease activity, preserved colon length, and alleviated histological inflammation. Mechanistically, CA downregulated RORγt levels and promoted Th cell plasticity toward IL‐10‐producing phenotypes, resulting in diminished production of IFN‐γ and IL‐17. Dietary depletion of primary bile acid precursors and IL‐10 neutralization confirmed IL‐10‐dependent immunoregulation as a key mechanism. Additionally, synthetic derivatives of CA, similar to CA, attenuated DSS‐induced colitis by selectively expanding IL‐10‐producing Th cells. Collectively, these findings highlight CA and its synthetic derivatives as immunomodulatory candidates for the therapy of ulcerative colitis.

  • Testosterone Suppresses IL‐17 Expression by Targeting RORγt Functions

    by Akshay Binayke, Rajdeep Dalal, Charu Suri, Jyotsna Dandotiya, Srikanth Sadhu, Yashwant Kumar, Shailendra Asthana, Deepak Kumar Rathore, Amit Awasthi

    Th17 cells play a crucial role in autoimmune disease pathogenesis. However, the mechanisms behind the sex differences in immune responses, particularly women's higher susceptibility to autoimmune diseases, remain unclear. This study investigated the role of testosterone in modulating the IL‐17 response. IL‐17 levels and IL‐17‐expressing cells were compared between males and females, and testosterone's effect on Th17 differentiation was evaluated. In an imiquimod‐induced psoriasis mouse model, testosterone supplementation reduced psoriasis severity in female mice, whereas castration of male mice exacerbated psoriasis. Testosterone inhibited both in vitro Th17 differentiation and in vivo IL‐17 expression, correlating with reduced psoriasis severity. Molecular studies indicated that testosterone is an inverse agonist of related orphan receptor gamma (RORγt), a key transcription factor for IL‐17 expression. These findings offer mechanistic insights into how testosterone limits tissue inflammation in psoriasis and suggest a basis for developing novel testosterone derivatives to target RORγt and suppress Th17‐mediated inflammation.


  • Open Access

    Cytokine profiling identifies circulating IL-2, IL23 and sPD-L1 as prognostic biomarkers for treatment outcomes in Non-Small cell Lung Cancer patients undergoing anti-PD1 therapy

    by Kriti Jain, Anika Goel, Deepa Mehra, Deepak Kumar Rathore, Akshay Binayke, Shyam Aggarwal, Surajit Ganguly, Amit Awasthi, Evanka Madan, Nirmal Kumar Ganguly

    Background: This study investigates the predictive potential of circulating cytokines for response and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy. Materials and Methods: A cohort of 64 patients with advanced NSCLC receiving ICI therapy were included. Baseline serum samples were collected prior to ICI initiation and profiled using a multiplex cytokine panel. Logistic regression, Cox regression, and Kaplan-Meier survival analysis were employed to assess associations between cytokine levels, therapeutic response, progression-free survival (PFS), and overall survival (OS). Gene expression levels of key cytokines were validated in peripheral blood mononuclear cells (PBMCs) using quantitative real-time PCR. Results: Elevated baseline levels of IL-2, IL-23, and sPD-L1 were significantly associated with clinical response to ICI therapy. Among these, sPD-L1 emerged as an independent predictor of response (AUC = 0.87). Multivariate Cox regression showed IL-2 (HR = 0.67), sPD-L1 (HR = 0.15), and IL-23 (HR = 1.18) were significantly associated with PFS and also predictive of OS. Notably, combined profiling of IL-2 and sPD-L1 enhanced predictive power (AUC = 0.95 for both PFS and OS). RT-PCR analysis of PBMCs corroborated these findings, confirming upregulation of IL-2 in responders and elevated IL-23 expression in non-responders. Conclusion: Baseline cytokine profiling particularly of IL-2, sPD-L1, and IL-23 provides important prognostic and predictive information in advanced NSCLC patients undergoing ICI therapy. These biomarkers may facilitate more personalized approaches to immunotherapy and guide clinical decision-making.

  • Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study

    by Archana Sasi, Jyotsna Dandotiya, Jyotsana Kaushal, Shuvadeep Ganguly, Akshay Binayke, K.M. Ambika, Akshi Shree, Farhana Jahan, Priyanka Sharma, Tejas Menon Suri, et al.

  • Open Access

    A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation

    by Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, Savita Singh, Priyanka Sharma, Rucha Chandwaskar, Mudita Gosain, Sreevatsan Raghavan, Deepika Rathna Murugesan, Pallavi Kshetrapal, et al.

    Measuring SARS-CoV-2-specific T cell responses is crucial to understanding an individual’s immunity to COVID-19. However, high inter- and intra-assay variability make it difficult to define T cells as a correlate of protection against COVID-19. To address this, we performed systematic review and meta-analysis of 495 datasets from 94 original articles evaluating SARS-CoV-2-specific T cell responses using three assays – Activation Induced Marker (AIM), Intracellular Cytokine Staining (ICS), and Enzyme-Linked Immunospot (ELISPOT), and defined each assay’s quantitative range. We validated these ranges using samples from 193 SARS-CoV-2-exposed individuals. Although IFNγ ELISPOT was the preferred assay, our experimental validation suggested that it under-represented the SARS-CoV-2-specific T cell repertoire. Our data indicate that a combination of AIM and ICS or FluoroSpot assay would better represent the frequency, polyfunctionality, and compartmentalization of the antigen-specific T cell responses. Taken together, our results contribute to defining the ranges of antigen-specific T cell assays and propose a choice of assay that can be employed to better understand the cellular immune response against viral diseases.


  • Antiviral activity of the human endogenous retrovirus‐R envelope protein against SARS‐CoV‐2

    by Shabnam Ansari, Nidhi Gupta, Rohit Verma, Oinam N Singh, Jyoti Gupta, Amit Kumar, Mukesh Kumar Yadav, Akshay Binayke, Mahima Tiwari, Neha Periwal, et al.


  • Open Access

    Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19

    by Akshay Binayke, Aymaan Zaheer, Jyotsna Dandotiya, Sonu Kumar Gupta, Shailendra Mani, Manas Ranjan Tripathy, Upasna Madan, Tripti Shrivastava, Yashwant Kumar, Anil Kumar Pandey, et al.

    The underlying factors contributing to the evolution of SARS-CoV-2-specific T cell responses during COVID-19 infection remain unidentified. To address this, we characterized innate and adaptive immune responses with metabolomic profiling longitudinally at three different time points (0–3, 7–9, and 14–16 days post-COVID-19 positivity) from young, mildly symptomatic, active COVID-19 patients infected during the first wave in mid-2020. We observed that anti-RBD IgG and viral neutralization are significantly reduced against the delta variant, compared to the ancestral strain. In contrast, compared to the ancestral strain, T cell responses remain preserved against the delta and omicron variants. We determined innate immune responses during the early stage of active infection, in response to TLR 3/7/8-mediated activation in PBMCs and serum metabolomic profiling. Correlation analysis indicated PBMCs-derived proinflammatory cytokines, IL-18, IL-1β, and IL-23, and the abundance of plasma metabolites involved in arginine biosynthesis were predictive of a robust SARS-CoV-2-specific Th1 response at a later stage (two weeks after PCR positivity). These observations may contribute to designing effective vaccines and adjuvants that promote innate immune responses and metabolites to induce a long-lasting anti-SARS-CoV-2-specific T cell response.


  • Open Access

    Proinflammatory innate cytokines and metabolomic signatures shape the T cell response in active COVID-19

    by Akshay Binayke, Aymaan Zaheer, Jyotsna Dandotiya, Sonu K Gupta, Shailendra Mani, Manas Tripathi, Upasna Madan, Tripti Shrivastava, Yashwant Kumar, Anil K Pandey, et al.

    The underlying factors contributing to the evolution of SARS-CoV-2-specific T cell response during COVID-19 infection remain unidentified. To address this, we characterized innate and adaptive immune responses with metabolomic profiling longitudinally at three different time points (0-4, 7-9, and 14-16 days post-COVID-19 positivity) from young mildly symptomatic active COVID-19 patients who got infected with ancestral virus. We observed the induction of anti-RBD and SARS-CoV-2 neutralizing antibodies together with antigen-specific T cell responses as early as 0-4 days post-infection. T cell responses were largely preserved against the delta and omicron variants as compared to the ancestral strain. We determined innate immune responses at an early (days 0-4 post-COVID-19 positivity) time point of active infection in response to TLR 3/7/8 mediated activation. Interestingly, the innate immune response exhibited by the elevated levels of IL-6, IL-1β, and IL-23 correlated with a robust SARS-CoV-2-specific Th1 response at the later time point (14-16 days post covid positivity). To further understand the association of metabolic pathways induced upon active COVID-19 infection with innate and T cell response, metabolomic profiling was performed. As compared to healthy individuals, COVID-19 patients displayed a distinct metabolic signature with an enrichment of pyroglutamate, itaconate, and azelaic acid, which correlated with the SARS-CoV-2-induced innate and T cells response. Our observations reveal mechanisms and potential interventional approaches that may assist in COVID-19 therapeutics and vaccine adjuvant strategies. One Sentence Summary T cell Immune response against SARS-CoV-2 is driven by a proinflammatory innate immune response and an associated metabolic signature in young adults.


  • Open Access

    Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection

    by Zaigham Abbas Rizvi, Rajdeep Dalal, Srikanth Sadhu, Akshay Binayke, Jyotsna Dandotiya, Yashwant Kumar, Tripti Shrivastava, Sonu Kumar Gupta, Suruchi Aggarwal, Manas Ranjan Tripathy, et al.

    Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the Golden Syrian hamster causes lung pathology that resembles human coronavirus disease (COVID-19). However, extrapulmonary pathologies associated with SARS-CoV-2 infection and post-COVID sequelae remain to be understood. Here, we show, using a hamster model, that the early phase of SARS-CoV-2 infection leads to an acute inflammatory response and lung pathologies, while the late phase of infection causes cardiovascular complications (CVCs) characterized by ventricular wall thickening associated with increased ventricular mass/body mass ratio and interstitial coronary fibrosis. Molecular profiling further substantiated our findings of CVC as SARS-CoV-2-infected hamsters showed elevated levels of serum cardiac troponin I, cholesterol, low-density lipoprotein, and long-chain fatty acid triglycerides. Serum metabolomics profiling of SARS-CoV-2-infected hamsters identified N-acetylneuraminate, a functional metabolite found to be associated with CVC, as a metabolic marker was found to be common between SARS-CoV-2-infected hamsters and COVID-19 patients. Together, we propose hamsters as a suitable animal model to study post-COVID sequelae associated with CVC, which could be extended to therapeutic interventions.